MTOR and neoplasm: Dapagliflozin, another SGLT2 inhibitor, could inhibit tumor growth and cancer proliferation by targeting the adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway [14].